Protagen AG. a leading provider of pharma development services, novel diagnostic tests and companion diagnostics in the fields of immuno-oncology and autoimmune disease, today announced changes to their Management Board. Dr. Georg Lautscham will join the company’s Management Board and Dr. Stefan Müllner will resign from his position as CEO.

This announcement follows recent changes to the company’s Supervisory Board of Directors, and accelerates the company’s evolution from development stage, into a successful commercial business.

Stefan Müllner, CEO of Protagen, stated: “The process of building Protagen to its current stage has been very rewarding for me personally. I look forward to supporting Protagen in a consulting capacity to help shape the company’s promising future.”

Dr. Kirschbaum, Chairman of the Protagen Board, commented: “I would like to welcome Georg into his new role. It is a natural transition for Georg, having served as the company’s Chief Business Officer for the past 3 years. This change underscores our focus on commercialization of our product portfolio. At the same time I would like to thank Stefan for his long standing commitment to Protagen and his willingness to further support the company in a consultancy role.”

“Together with Peter Schulz-Knappe, CSO, another member of the Management Board, I look forward to building upon our recent successes with collaboration and licensing. In our pharma collaboration business we now work with 4 out of the top 10 Pharma companies and we have also closed a licensing deal with the global leader in autoimmune disease diagnostics”, added Georg Lautscham. “I would like to extend my sincere thanks to Stefan and to the Protagen team for their high quality work that has laid the foundation for the great future which lies ahead of us.”

About Protagen AG – Diagnostics Differentiated

Headquartered in Dortmund Germany, Protagen specializes in Pharma development services, novel diagnostics and companion diagnostics, in the field of immune-oncology and autoimmune disease. Protagen uses its proprietary SeroTag® biomarker discovery platform to identify valuable biomarkers that support Pharma development and personalize treatment with targeted therapies.

With pioneering bioscience techniques, extensive scientific expertise and a broad patent portfolio, Protagen is expanding its own pipeline of critically informative biomarkers and collaborates with other organizations to commercialize valuable tools for better personalized treatment strategies.

Dr. Georg Lautscham
T +49 231 9742 6300

Media Enquiries
Dr. Clare Russell
Managing Director
T +44 1223 253787 M +44 7812 343412